Osiris Scores $225M DoD Contract for Acute Radiation Syndrome Treatment with Prochymal Adult Stem Cell Product

Posted on January 12, 2008 by jrowley

Osiris Therapeutics announced that they won a DoD contract worth up to $224.7 million for developing their adult mesenchymal stem cell (MSC)-based therapeutic for treating acute radiation exposure. The contract allows for reimbursement of up to $24.7 million for continued development of their Prochymal product, and then, once the product is FDA approved for acute [...]

Filed under: adult stem cell, business models, Clinical Trials, DoD, MSCs, Osiris, Regenerative Medicine, stem cells | Tagged: , , , , , | 1 Comment »

Chinese CRO WuXi Pharmatech Acquires Apptec Laboratory Services

Posted on January 7, 2008 by jrowley

WuXi (pronounced Woo-See) Pharmatech, a contract research organization (CRO) based in China, announced the acquisition of MN-based Apptec Laboratory Services. WuXi acquired Apptec to gain an immediate US footprint, better access to the US market, and important biologics expertise to expand outside the world of small molecules. This biologics expertise includes Apptec’s cell therapy bioproduction [...]

Filed under: Apptec, BD, Bioprocessing, business models, Company Profiles, Invitrogen, JNJ, Lonza, Manufacturing, Regenerative Medicine, WuXi Pharmatech | 1 Comment »

New Year’s Resolutions for the Regenerative Medicine Industry

Posted on January 2, 2008 by jrowley

With the New Year upon us, I thought it would be good to make a set of New Year’s Resolutions for the regenerative medicine industry. This set of resolutions is not company specific, but things that will be required to build long term value for this nascent industry. Get those marketing people working: Any way [...]

Filed under: business models, Innovation, Regenerative Medicine | Tagged: , , , | 2 Comments »

BioTime Births Embryome Sciences

Posted on December 19, 2007 by jrowley

There have been some interesting news releases this week, including Osiris’ fast track designation, Cytori obtaining a 510k for their fat cleaner (not their stem cell isolation device, just a clinical fat cleaner), and the angiogenesis and liver regeneration capabilities of Aldagen’s aldehyde dehydrogenase positive sorted cells. However, the press release that really caught my [...]

Filed under: Bioprocessing, BioTime, business models, Embryome Sciences, Regenerative Medicine | Tagged: , , , , , | Leave a Comment »

Organogenesis Expands into China

Posted on December 13, 2007 by jrowley

Organogenesis, one of the pioneering tissue engineering companies, is partnering with China’s National Tissue Engineering Center (NTEC) to bring Organogenesis’ regenerative therapies to the Chinese marketplace. NTEC is a Shanghai-based private company that is funded by the Chinese government, and it was launched by a Harvard/MIT-trained plastic surgeon, Dr. Yiling Cao. The two companies look [...]

Filed under: Bioprocessing, business models, Joint Ventures, Manufacturing, Regenerative Medicine | Tagged: , , , , | 1 Comment »

Biomaterials as Therapies

Posted on December 9, 2007 by jrowley

The regenerative medicine industry is banking on cellular therapy to help regenerate tissues and restore function in clinical indications with high unmet needs. The mechanism of action, or how stem cells actually drive tissue regeneration, is still hotly debated – but it is likely a mixture of several actions (see item #6 in this post) [...]

Filed under: Biomaterials, business models, Regenerative Medicine | Tagged: , , | 1 Comment »

  • Subscribe via email

    Subscribe to The Regeneration Station by Email

  • Top Posts

  • a

Follow

Get every new post delivered to your Inbox.